Biology of Blood and Marrow Transplantation · 2012 · 88 citations · 34 references
MedicineOncologyChemotherapyCytogeneticsMolecular OncologyCancer CytogeneticsClinical CytogeneticsHematologic Malignancy TherapyHigh-dose ChemotherapyMolecular CytogeneticsMultiple MyelomaClinical RemissionCytogenetic Risk StratificationHigh-risk Multiple MyelomaMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentSurvival After Autologous TransplantationTandem Transplantation
Within a prospective protocol, the incidence and impact of achievement of molecular remission (mCR) and high-risk cytogenetics was investigated in 73 patients with multiple myeloma (MM) after autologous (auto)-allogeneic (allo) tandem stem cell transplantation (SCT). After induction chemotherapy, patients received melphalan 200 mg/m(2) before undergoing auto-SCT, followed 3 months later by melphalan 140 mg/m(2) and fludarabine 180 mg/m(2) before allo-SCT. Sixteen patients had high-risk cytogenetic features, defined by positive FISH for del(17p13) and/or t(4;14). Overall, 66% of the patients achieved CR or near-CR, and 41% achieved mCR, which was sustained negative (at least 4 consecutive samples negative) in 15 patients (21%), with no significant difference in incidence between the patients with high-risk cytogenetics and others (P = .70). After a median follow-up of 6 years, overall 5-year progression-free survival was 29%, with no significant difference between del 17p13/t(4;14)-harboring patients and others (24% versus 30%; P = .70). The 5-year progression-free survival differed substantially according to the achieved remission: 17% for partial remission, 41% for CR, 57% for mCR, and 85% for sustained mCR. These results suggest that auto-allo tandem SCT may overcome the negative prognostic effect of del(17p13) and/or t(4;14) and that achievement of molecular remission resulted in long-term freedom from disease.
34
International uniform response criteria for multiple myeloma
Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations
Medicine, Hematology, Oncology +12
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Benedetto Bruno, Marcello Rotta, Francesca Patriarca et al. · New England Journal of Medicine · 2007 · 504 citations
Medicine, Hematology, Oncology +16